KEY MARKET OPPORTUNITIES WITH C3 REDUCT®

Healthy living and wellness through organ health

2020, there has been growing consumer demand for health products in Europe, immunity-boosting and organ-health supplements. This is expected to be a trend. Unsurprisingly, the global coronavirus pandemic has been one of the main factors driving this trend, as consumers seek to improve their immune systems.

consumer expectations for functional, natural clean-label products, nutraceutical companies need to increase the effectiveness of their ingredients and products.

can help manufacturers appeal to consumers looking for science-backed enhanced and targeted functionality. For example, fibrosis in various organsthe lungs and the liver – can occur for a variety of reasons and is a common While this can occur due to variety of reasons, inflammation is the key denominator development. A key issue is the fact that current pharmaceuticals have difficulty in treating this condition. This is where the effective, targeted antioxidant and anti-inflammatory properties of C3 Reduct® can help.

to lung health, in unpublished trials, C3 Reduct® has been shown to significantly expression of inflammatory markers such as IL-6 and IFNγ in lung tissues of rats with bleomycin-induced pulmonary fibrosis. For liver health, C3 Reduct® has been shown to be reducing inflammatory cell infiltration into the liver, which could enable developers to better target the market for liver health product.7 increasingly knowledgeable and aware of the influence of gut health on and are looking for products that support gut health in a preventive manner. C3 been shown to attenuate inflammatory responses and maintain colon health, by selectively inhibiting the enzymes of certain inflammatory pathways.8

C3 Reduct®- and healthy ageing

Europe’s ageing population is also driving demand for targeted products that support longevity, organ health and general wellbeing. Ageing is associated with degenerative muscular and skeletal conditions and neurological conditions such as Alzheimer’s.

Better awareness among seniors of the benefit of taking preventative measures - and the will to live independently for longer - is creating new opportunities for functional products that support healthy ageing. Indeed, the growing importance attached to this issue is underlined by the fact that the United Nations declared this decade to be the Decade of Healthy Ageing.9

Nutraceutical products that help consumers to maintain brain health is a category that is only set to grow, and C3 Reduct® possesses excellent antioxidant and anti-inflammatory properties. In trials, THC, the major ingredient in C3 Reduct®, has been shown to reduce inflammation and thus neurodegeneration, because it possesses anti-amyloid activity. THC has also been shown to help reduce glutathione in the brains of diabetic rats, suggesting efficacy in protecting against lipid peroxidation-induced membrane damage.10

Another key issue with regards to healthy ageing is joint health, and the anti-inflammatory properties of C3 Reduct® hold significant promise in this field. Osteoarthritis (OA) is a chronic joint condition, affecting over 250 million people worldwide11 . Ongoing studies and existing literature beckon a promising role for the anti-arthritic effects of THC in OA and rheumatoid arthritis (RA). In particular, THC - but not curcumin - was shown to prevent glucose intolerance, which might be involved in exacerbating osteoarthritis.12

7. Pari L, Murugan P. 2005. Effect of tetrahydrocurcumin on blood glucose, plasma insulin and hepatic key enzymes in streptozotocin induced diabetic rats. Journal of Basic and Clinical Physiology and Pharmacology. 16(4): 257-274

8. Lai CS, Wu JC, Yu SF, Badmaev V, Nagabhushanam K, Ho CT, Pan MH. 2011. Tetrahydrocurcumin is more effective than curcumin in preventing azoxymethane‐induced colon carcinogenesis. Molecular Nutrition and Food Research. 55(12): 1819-1828

9. https://www.who.int/initiatives/decade-of-healthy-ageing

10. Aynun N. et. al. 2008. Curcumin Structure-Function, Bioavailability, and Efficacyin Models of Neuroinflammation and Alzheimer’s Disease. The Journal of pharmacology and Experimental Therapeutics. 326:196–208

11 Hunter D.J., Schofield D., Callander E. The individual and socioeconomic impact of osteoarthritis. Lancet Nat. Rev. Rheumatol. 2014; 10:437–441. doi: 10.1038/nrrheum.2014.44.

12. Park S. et. al. 2016. Curcumin and tetrahydrocurcumin both prevent osteoarthritis symptoms and decrease the expressions of pro-inflammatory cytokines in estrogen-deficient rats. Genes & Nutrition. 11:2